InsidersTradesSigma
Total declarations
Company
▲ Purchases (9 ops.)
▼ Sales (0 ops.)
Browse the full record of transactions filed by Altman Peter, Chairman & CEO. Insider active across 1 companies, notably BioCardia, Inc.. Cumulatively, 13 reports have been logged. Total volume traded: €57k. The latest transaction was filed on 15 May 2026 — Acquisition. Regulator: SEC (Form 4). The full history is free.
Declarations13 total
€4,4735,100 shares@ €0.8777.0% of flow
Common Stock
SEC:0001437749-26-017459·
Ideal exit: 9 Feb 2027 (T+270)
€4,4735,100 shares@ €0.8770.040% mcap2.5% of flow
Common Stock
SEC:0001437749-26-017459:0·
Ideal exit: 9 Feb 2027 (T+270)
€6,1874,500 shares@ €1.37490.056% mcap3.4% of flow
Common Stock
SEC:0001437749-22-014899:0·
Ideal exit: 7 Mar 2023 (T+270)
€39,99131,446 shares@ €1.27170.36% mcap22.3% of flow
Common Stock
SEC:0001437749-22-012954:0·
€1,2371,000 shares@ €1.23660.011% mcap0.7% of flow
Common Stock
SEC:0001437749-22-012420:0·
Ideal exit: 5 Feb 2023 (T+270)
€3,4812,300 shares@ €1.51370.032% mcap1.9% of flow
Common Stock
SEC:0001437749-22-010339:0·
Ideal exit: 23 Jan 2023 (T+270)
076,734 shares0
Common Stock
SEC:0001437749-22-009166:0·
€9,7165,000 shares@ €1.943315.1% of flow
Common Stock
SEC:0001437749-21-027108·
Ideal exit: 15 Aug 2022 (T+270)
€9,7165,000 shares@ €1.94330.088% mcap5.4% of flow
Common Stock
SEC:0001437749-21-027108:0·
Ideal exit: 15 Aug 2022 (T+270)
€8,7883,500 shares@ €2.510713.7% of flow
Common Stock
SEC:0001437749-21-020444·
Ideal exit: 14 May 2022 (T+270)
€8,7883,500 shares@ €2.51070.080% mcap4.9% of flow
Common Stock
SEC:0001437749-21-020444:0·
Ideal exit: 14 May 2022 (T+270)
€41,35411,572 shares@ €3.57360.37% mcap23.0% of flow
Common Stock
SEC:0001437749-21-014634:0·
€41,35411,572 shares@ €3.573664.3% of flow
Common Stock
SEC:0001437749-21-014634·
13 of 13 declarations
About Altman Peter
Peter Altman is the President and CEO of BioCardia, Inc. He is responsible for the strategic direction of the company and overall management of operations. His role is essential in ensuring innovation and growth for BioCardia in the biotechnology sector.
